107. 若年性特発性関節炎 Juvenile idiopathic arthritis Clinical trials / Disease details
臨床試験数 : 447 / 薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146
Showing 1 to 10 of 79 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05609630 (ClinicalTrials.gov) | March 15, 2023 | 7/11/2022 | Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumabto Evaluate Change in Disease Act ... | A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of U ... | Juvenile Idiopathic Arthritis | Drug: Upadacitinib;Drug: Tocilizumab | AbbVie | NULL | Not yet recruiting | 1 Year | 17 Years | All | 90 | Phase 3 | NULL |
| 2 | NCT03301883 (ClinicalTrials.gov) | April 26, 2018 | 21/9/2017 | A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA) | A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizum ... | Juvenile Idiopathic Arthritis | Drug: Tocilizumab;Drug: NSAIDs;Drug: CSs;Drug: MTX | Hoffmann-La Roche | NULL | Completed | 2 Years | 17 Years | All | 62 | Phase 4 | China |
| 3 | ChiCTR-OPB-17013704 | 2017-12-20 | 2017-12-05 | A phase IV, multicenter single-arm, open-label study to assess the efficecy and safety of Tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis A phase IV, multicenter single-arm, open-label study to assess the efficecy and safety of Tocilizuma ... | A phase IV, multicenter single-arm, open-label study to assess the efficecy and safety of Tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis A phase IV, multicenter single-arm, open-label study to assess the efficecy and safety of Tocilizuma ... | systemic juvenile idiopathic arthritis | Case series:Tocilizumab; | Children's Hospital of Chongqing Medical University | NULL | Recruiting | 2 | 17 | Both | Case series:65; | Phase 4 | China |
| 4 | ChiCTR-INR-17011829 | 2017-08-01 | 2017-07-02 | Multiple center's clinical treatment of systemic onset juvenile idiopathic arthritis with tocilizumab Multiple center's clinical treatment of systemic onset juvenile idiopathic arthritis with tocilizuma ... | Multiple center's clinical treatment of systemic onset juvenile idiopathic arthritis with tocilizumab Multiple center's clinical treatment of systemic onset juvenile idiopathic arthritis with tocilizuma ... | Systemic onset juvenile idiopathic arthritis | Case:Tocilizumab;Control:Conventional Treatment; | Shenzhen Children's Hospital | NULL | Pending | Both | Case:75;Control:75; | China | |||
| 5 | NCT02840175 (ClinicalTrials.gov) | May 18, 2017 | 19/7/2016 | Treatment Tapering in JIA With Inactive Disease | Treatment Tapering in Oligoarticular or Rheumatoid Factor Negative Polyarticular Juvenile Idiopathic Arthritis With Inactive Disease on Biologic Therapy Treatment Tapering in Oligoarticular or Rheumatoid Factor Negative Polyarticular Juvenile Idiopathic ... | Juvenile Idiopathic Arthritis | Drug: etanercept;Drug: adalimumab;Drug: Abatacept;Drug: Tocilizumab | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 2 Years | 17 Years | All | 62 | Phase 3 | France |
| 6 | JPRN-UMIN000024178 | 2016/09/28 | 28/09/2016 | Efficacy and safety of combination therapy of tocilizumab and abatacept in patients with refractory systemic-onset juvenile idiopathic arthritis Efficacy and safety of combination therapy of tocilizumaband abatacept in patients with refractory s ... | Efficacy and safety of combination therapy of tocilizumab and abatacept in patients with refractory systemic-onset juvenile idiopathic arthritis - Efficacy and safety of combination therapy of tocilizumab and abatacept in patients with refractory systemic-onset juvenile idiopathic arthritis Efficacy and safety of combination therapy of tocilizumaband abatacept in patients with refractory s ... | Systemic-onset juvenile idiopathic arthritis(sJIA) | Tocilizumab 8mg/kg every 2 weeks, and Abatacept 10 mg/kg every 4 weeks | Yokohama City University Hospital Department of Pediatrics | NULL | Recruiting | 2years-old | Not applicable | Male and Female | 5 | Not selected | Japan |
| 7 | ChiCTR-OPC-17011391 | 2016-09-01 | 2017-05-12 | The efficacy and safety of tocilizumab for refractory systemic juvenile idiopathic arthritis in China The efficacy and safety of tocilizumabfor refractory systemic juvenile idiopathic arthritis in China ... | The efficacy and safety of tocilizumab for refractory systemic juvenile idiopathic arthritis in China The efficacy and safety of tocilizumabfor refractory systemic juvenile idiopathic arthritis in China ... | systemic juvenile idiopathic arthritis | tocilizumab group:tocilizumab;glucocorticoid group:glucocorticoid; | Children's Hospital of Chongqing Medical University | NULL | Completed | 2 | 16 | Both | tocilizumab group:36;glucocorticoid group:24; | China | |
| 8 | EUCTR2016-000312-15-FR (EUCTR) | 12/08/2016 | 17/06/2016 | Treatment tapering in oligoarticular or rheumatoid factor negative polyarticular Juvenile Idiopathic Arthritis with inactive disease on biologic therapy - AJIBIOREM Treatment tapering in oligoarticular or rheumatoid factor negative polyarticular Juvenile Idiopathic ... | Treatment tapering in oligoarticular or rheumatoid factor negative polyarticular Juvenile Idiopathic Arthritis with inactive disease on biologic therapy - AJIBIOREM Treatment tapering in oligoarticular or rheumatoid factor negative polyarticular Juvenile Idiopathic ... | Patients with oligoarticular onset or rheumatoid factor negative polyarticular JIA followed in tertiary care center for paediatric rheumatology. MedDRA version: 19.0;Level: PT;Classification code 10059176;Term: Juvenile idiopathic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders Patients with oligoarticular onset or rheumatoid factor negative polyarticular JIA followed in terti ... | Trade Name: ENBREL Product Name: ENBREL INN or Proposed INN: Etanercept Other descriptive name: Etanercept Trade Name: HUMIRA Product Name: HUMIRA INN or Proposed INN: adalimumab Other descriptive name: adalimumab Trade Name: ROACTEMRA Product Name: ROACTEMRA INN or Proposed INN: tocilizumab Other descriptive name: tocilizumab Trade Name: ORENCIA Product Name: ORENCIA INN or Proposed INN: abatacept Other descriptive name: abatacept Trade Name: ENBREL Product Name: ENBREL INN or Proposed INN: Etanercept Other descriptive name: Etanerc ... | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | Not Recruiting | Female: yes Male: yes | 230 | Phase 3 | France | ||
| 9 | EUCTR2015-000435-33-GB (EUCTR) | 18/08/2015 | 17/07/2015 | A study to assess the pharmacokinetics and safety of tocilizumab in patients less than 2 years old with Active Systemic Juvenile Idiopathic Arthritis. A study to assess the pharmacokinetics and safety of tocilizumabin patients less than 2 years old wi ... | A phase I pharmacokinetic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA) A phase I pharmacokinetic and safety study of tocilizumab(TCZ) in patients less than 2 years old wit ... | Systemic Juvenile Idiopathic Arthritis (sJIA) MedDRA version: 19.0;Level: PT;Classification code 10059176;Term: Juvenile idiopathic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Systemic Juvenile Idiopathic Arthritis (sJIA) MedDRA version: 19.0;Level: PT;Classification code 100 ... | Trade Name: Roactemra INN or Proposed INN: tocilizumab Other descriptive name: IL-6 receptor inhibitor, recombinant humanized monoclonal antibody Trade Name: Roactemra INN or Proposed INN: tocilizumab Other descriptive name: IL-6 receptor inhibitor ... | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 10 | Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - ( ... | France;Hungary;Poland;Belgium;Spain;Russian Federation;Germany;Italy;United Kingdom | ||
| 10 | EUCTR2015-000435-33-BE (EUCTR) | 12/08/2015 | 19/06/2015 | A study to assess the pharmacokinetics and safety of tocilizumab in patients less than 2 years old with Active Systemic Juvenile Idiopathic Arthritis. A study to assess the pharmacokinetics and safety of tocilizumabin patients less than 2 years old wi ... | A phase I pharmacokinetic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA) A phase I pharmacokinetic and safety study of tocilizumab(TCZ) in patients less than 2 years old wit ... | Systemic Juvenile Idiopathic Arthritis (sJIA) MedDRA version: 19.0;Level: PT;Classification code 10059176;Term: Juvenile idiopathic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Systemic Juvenile Idiopathic Arthritis (sJIA) MedDRA version: 19.0;Level: PT;Classification code 100 ... | Trade Name: Roactemra INN or Proposed INN: tocilizumab Other descriptive name: IL-6 receptor inhibitor, recombinant humanized monoclonal antibody Trade Name: Roactemra INN or Proposed INN: tocilizumab Other descriptive name: IL-6 receptor inhibitor ... | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 1 | France;Hungary;Poland;Spain;Belgium;Russian Federation;Germany;Italy;United Kingdom |